Apolipoprotein e4 allele and cognitive decline in elderly men.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 7987151.
- Also identified by PMC identifier 2541698.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To determine whether polymorphism of apolipoprotein E--notably, the e4 allele--predicts cognitive deterioration in the general population. Population based cohort investigated in 1990 and in 1993. Zutphen, the Netherlands. Representative cohort of 538 Dutch men aged 70-89 at baseline. Cognitive function assessed by mini mental state examination, change in cognitive function and incidence of impaired cognitive function at three years. The baseline prevalence of impaired cognitive function (mini mental state examination score < or = 25) was higher among carriers of the e4 allele compared with men without the allele (41.0% (55) v 31.1% (122) P = 0.03), and this result was still valid after adjustment for age, occupation, smoking, alcohol use, and cardiovascular diseases. The decline in cognitive function at three years was largest in men homozygous for e4 (-2.4 points), intermediate in those heterozygous for e4 (-0.7 points), and lowest in men without e4 (-0.1 points), and it was independent of other risk factors (P = 0.02). The risk of developing impaired cognitive function during follow up was significantly increased in allele carriers compared with non-carriers (27.6% (16/58) v 15.5% (32/207)). The adjusted odds ratio was 2.87 (95% confidence interval 1.29 to 6.42). Twenty two per cent of the risk of developing impaired cognitive function in this population may be attributable to the e4 allele. The apolipoprotein e4 allele predisposes to cognitive decline in a general population of elderly men.
Medical subject headings
- Apolipoproteins E
- Cognition Disorders